Comparative Pharmacology
Head-to-head clinical analysis: NEO CORT DOME versus NEO MEDROL ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORT DOME versus NEO MEDROL ACETATE.
NEO-CORT-DOME vs NEO-MEDROL ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Hydrocortisone is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors and modulating gene expression.
Methylprednisolone acetate is a corticosteroid with glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression, suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes), and inhibition of immune cell proliferation and function.
Apply topically to affected area twice daily.
Intra-articular, intrabursal, or periarticular injection: 4-40 mg depending on joint size. For intralesional injection: 10-40 mg per lesion. For systemic use (intramuscular): 40-120 mg every 1-5 weeks as needed.
None Documented
None Documented
2–3 hours (terminal elimination half-life of hydrocortisone); clinically, duration of action is longer due to intracellular receptor binding.
Terminal half-life approximately 24-36 hours; prolonged in hepatic impairment; sufficient for once-daily dosing.
Renal excretion of hydrocortisone metabolites (primarily conjugated as glucuronides and sulfates) accounts for >90% of elimination; <5% biliary/fecal.
Primarily renal: ~75-90% as metabolites and <5% unchanged. Biliary/fecal: ~10-25%.
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic